Clinical trials, progression-speed differentiating features and swiftness rule of the innovative targets of first-in-class drugs
Yinghong Li(Chongqing University of Posts and Telecommunications), Feng Zhu(Zhejiang University), Weiwei Xue(Nanjing University of Chinese Medicine), Fengcheng Li(Zhejiang University), Hong Yang(Chonnam National University), Yu Jiang(Jingdezhen Ceramic Institute), Yu Chen(National University of Singapore), Xiao Xu Li(Chongqing University), Yunxia Wang(University of Kansas Medical Center), Chun Yan Yu(Chongqing University), Jianbo Fu(Zhejiang University), Jia Jun Hong(Zhejiang University), Jie Hu(Southwestern University of Finance and Economics)
Cited by 158
Related Papers
Mechanisms of drug combinations: interaction and network perspectives
|Nature Reviews Drug Discovery|2009|954
Therapeutic target database 2020: enriched resource for facilitating research and early development of targeted therapeutics
|Nucleic Acids Research|2019|830
Therapeutic target database update 2022: facilitating drug discovery with enriched comparative data of targeted agents
|Nucleic Acids Research|2021|710
Comparative genetic architectures of schizophrenia in East Asian and European populations
|Nature Genetics|2019|709
HawkDock: a web server to predict and analyze the protein–protein complex based on computational docking and MM/GBSA
|Nucleic Acids Research|2019|646